Secukinumab in Ankylosing Spondylitis Patients: A Cost-per-Responder Analysis from the Indonesian Health System Perspective.

ABSTRACT:

Objective

There are no publications that have demonstrated economic value for ankylosing spondylitis (AS) treatments in Indonesia. Cost per responder (CPR) is a lean method of economic evaluation. We estimated CPR from Indonesia's health system perspective following AS treatment with secukinumab relative to adalimumab, golimumab, and infliximab.

Methods

In the absence of head-to-head trials, a comparative evidence analysis was conducted in the form of matching-adjusted indirect comparison (MAIC) to estimate the response rate of various competing treatment options against secukinumab. This was followed by a CPR analysis that compared the cost per patient for a defined response level.

Results

Based on MAIC, patients on secukinumab had higher Assessment in Spondyloarthri

SUBMITTER: Wahono CS 

PROVIDER: S-EPMC10333162 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature